Botox Cosmetic has long had a monopoly on the market for temporary wrinkle abatement around the eyes and forehead. Now, a new product known universally as Dysport has joined the market. This new product has a long history of success in Europe and was found there to be safe and effective. In fact, it has been used in twenty seven countries outside the United States. Until the recent approval by the U.S. Food and Drug Administration, it could not be marketed in the United States.
In the United States, Dysport will be sold by Medicis Pharmaceutical, whose Restylane was the first non-collagen filler to plump up lips and the creases between the lips and the mouth.
Some doctors who have had experience with both Botox Cosmetic and Dysport report that Dysport may in fact last longer than Botox. The company currently makes no such claim, however. Also reported is that it appears to be “faster acting” and to have a greater internal “spread” such that one can affect minimally the areas surrounding the immediate injection site.
Of course, it remains to be seen whether or not this is the experience of all MDs. My long experience has taught me that only when a product or procedure is used or put into place by the entire corps of physicians that the benefits – and downsides – of the new medication are fully appreciated.
—Robert Kotler, MD, FACS